Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of the study is to determine safety and tolerability of CVX-045 in patients with advanced solid tumors.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| CVX-045 | Biological | Weekly, intravenous dose |
|
| Measure | Description | Time Frame |
|---|---|---|
| To determine safety and tolerability of CVX-045 as weekly intravenous (IV) infusions in adult patients with advanced solid tumors | Throughout duration of study | |
| To identify and characterize CVX-045-related adverse events (AEs) | Throughout duration of study |
| Measure | Description | Time Frame |
|---|---|---|
| To evaluate the plasma pharmacokinetics (PK) of CVX-045 | Days 1, 4, 8, 15, 29 | |
| To determine a recommended Phase 2 dose of CVX-045 | End of study | |
| To evaluate the potential for immunogenicity of CVX-045 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pfizer CT.gov Call Center | Pfizer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Pfizer Investigational Site | Scottsdale | Arizona | 85258 | United States | ||
| Pfizer Investigational Site |
Not provided
| Label | URL |
|---|---|
| To obtain contact information for a study center near you, click here. | View source |
Not provided
Not provided
| ID | Term |
|---|---|
| D009369 | Neoplasms |
| D002277 | Carcinoma |
| ID | Term |
|---|---|
| D009375 | Neoplasms, Glandular and Epithelial |
| D009370 | Neoplasms by Histologic Type |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Days 1, 15, 1st day of every subsequent cycle, EOS, 30 Day FU |
| To document any preliminary evidence of antitumor activity | Every 8 weeks |
| Santa Monica |
| California |
| 90404 |
| United States |
| Pfizer Investigational Site | Philadelphia | Pennsylvania | 19111 | United States |